对非小细胞肺癌的治疗策略的最新进展
Po-Lan Su1,2, Naoki Furuya1,3, Alahmadi Asrar1,4
1Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
精准医学,包括向疗法和免疫疗法,已经改变了肺癌治疗. 新型药物,如双特异性抗体和抗体-药物合物,为高级非小细胞肺癌 (NSCLC) 提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺癌仍然是全球癌症相关死亡的主要原因.
- 使用向疗法和免疫疗法的精准医学显著改善了转移性非小细胞肺癌 (NSCLC) 的结果.
- 最近的研究强调了这些疗法在早期NSCLC的疗效,包括术后和化学放射治疗后的设置.
研究的目的:
- 审查最近非小细胞肺癌 (NSCLC) 治疗方法的进展.
- 讨论新兴的新药及其在不断变化的NSCLC治疗领域的挑战.
- 总结一下肺癌管理中的精准医学的现状.
主要方法:
- 最近临床试验和研究的文献综述.
- 对新型治疗药物的分析,包括双特异性抗体和抗体-药物联合体.
- 针对NSCLC的向治疗和免疫治疗的当前数据的综合.
主要成果:
- 向治疗和免疫治疗改善了转移性NSCLC的存活率.
- 阿米万他马布已被批准用于EGFR突变NSCLC,包括外20插入突变.
- 针对HER2,TROP2,HER3和MET的抗体药物联合体 (ADC) 显示出有希望的结果.
结论:
- 尽管取得了进展,但疾病的进展需要持续探索先进NSCLC的后续治疗策略.
- 新兴的双特异性抗体和ADCs代表了重大进展,扩大了治疗选择.
- 持续的研究对于优化和克服NSCLC治疗领域的挑战至关重要.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
